EA200600987A1 - APPLICATION OF SYRAMEZIN IN THE TREATMENT OF MALIGNANT TUMORS - Google Patents
APPLICATION OF SYRAMEZIN IN THE TREATMENT OF MALIGNANT TUMORSInfo
- Publication number
- EA200600987A1 EA200600987A1 EA200600987A EA200600987A EA200600987A1 EA 200600987 A1 EA200600987 A1 EA 200600987A1 EA 200600987 A EA200600987 A EA 200600987A EA 200600987 A EA200600987 A EA 200600987A EA 200600987 A1 EA200600987 A1 EA 200600987A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- malignant tumors
- syramezin
- application
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Настоящее изобретение относится к лечению злокачественных опухолей. В частности, изобретение относится к фармацевтическим композициям, содержащим сирамезин и предназначенным для лечения злокачественных опухолей. Изобретение также относится к способу лечения, включающему введение сирамезина пациенту, страдающему от злокачественной опухоли.The present invention relates to the treatment of malignant tumors. In particular, the invention relates to pharmaceutical compositions containing siramesin and intended for the treatment of malignant tumors. The invention also relates to a method of treatment comprising administering siramezin to a patient suffering from a malignant tumor.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53167003P | 2003-12-19 | 2003-12-19 | |
DKPA200301889 | 2003-12-19 | ||
PCT/DK2004/000885 WO2005058324A1 (en) | 2003-12-19 | 2004-12-17 | Use of siramesine in the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200600987A1 true EA200600987A1 (en) | 2006-10-27 |
EA011170B1 EA011170B1 (en) | 2009-02-27 |
Family
ID=34702153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200600987A EA011170B1 (en) | 2003-12-19 | 2004-12-17 | Use of siramesine in the treatment of cancer |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1715864A1 (en) |
JP (1) | JP2007514666A (en) |
AU (1) | AU2004298722A1 (en) |
BR (1) | BRPI0416019A (en) |
CA (1) | CA2550611A1 (en) |
EA (1) | EA011170B1 (en) |
NO (1) | NO20063319L (en) |
WO (1) | WO2005058324A1 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR030453A1 (en) * | 2000-08-15 | 2003-08-20 | Lundbeck & Co As H | PHARMACEUTICAL COMPOSITION WITH CONTENT OF 1 '[4- [1- (4-FLUOROPHENIL) -1H-INDOL-3-IL] -1-BUTIL] ESPIRO [ISOBENZOFURAN-1 (3H), 4'-PIPERIDINE] |
US6436938B1 (en) * | 2001-01-22 | 2002-08-20 | Pfizer Inc. | Combination treatment for depression |
-
2004
- 2004-12-17 EA EA200600987A patent/EA011170B1/en not_active IP Right Cessation
- 2004-12-17 CA CA002550611A patent/CA2550611A1/en not_active Abandoned
- 2004-12-17 AU AU2004298722A patent/AU2004298722A1/en not_active Abandoned
- 2004-12-17 EP EP04803036A patent/EP1715864A1/en not_active Withdrawn
- 2004-12-17 JP JP2006544219A patent/JP2007514666A/en active Pending
- 2004-12-17 BR BRPI0416019-3A patent/BRPI0416019A/en not_active IP Right Cessation
- 2004-12-17 WO PCT/DK2004/000885 patent/WO2005058324A1/en active Application Filing
-
2006
- 2006-07-18 NO NO20063319A patent/NO20063319L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2007514666A (en) | 2007-06-07 |
NO20063319L (en) | 2006-07-18 |
EA011170B1 (en) | 2009-02-27 |
EP1715864A1 (en) | 2006-11-02 |
CA2550611A1 (en) | 2005-06-30 |
AU2004298722A1 (en) | 2005-06-30 |
WO2005058324A1 (en) | 2005-06-30 |
BRPI0416019A (en) | 2007-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE442142T1 (en) | FREDERICAMYCIN DERIVATIVES AS DRUGS FOR TUMOR TREATMENT | |
MY169308A (en) | Treatment of tnf? related disorders | |
DE60028970D1 (en) | AT HER2 BINDING PEPTIDE COMPOUNDS | |
EA200601212A1 (en) | PHOSPHODESTERASE INHIBITORS, OBTAINING AND THEIR THERAPEUTIC APPLICATION | |
MX2007002269A (en) | Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain. | |
DE50310516D1 (en) | Fredericamycin DERIVATIVES | |
NO20071426L (en) | Cancer combination therapy including AZD2171 and Imatinib | |
IL171974A0 (en) | Tetrahydrocarbazole derivatives and their pharmaceutical use | |
BR0306715A (en) | Methods for diagnosis and treatment of tumors | |
EA200500244A1 (en) | TETRAPROPILAMMONIA TETRATIOMOLYBDAT AND RELATED COMPOUNDS FOR ANTIANGIOGENIC THERAPY | |
IS6558A (en) | Mixed disease treatment with vasoconstrictor | |
SE0300098D0 (en) | Use of cyclin D1 inhibitors | |
EA200501821A1 (en) | PHARMACEUTICAL COMBINATION, CONTAINING MODAFINIL AND OTHER DRUG PREPARATION | |
WO2004073615A3 (en) | Deazaflavin compounds and methods of use thereof | |
DE60311788D1 (en) | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | |
HK1074840A1 (en) | Novel dithiolopyrrolones with therapeutic activity | |
EA200600987A1 (en) | APPLICATION OF SYRAMEZIN IN THE TREATMENT OF MALIGNANT TUMORS | |
DE502005010237D1 (en) | STABLE DOSAGE FOR PHENYLALANINE DERIVATIVES | |
MXPA05013975A (en) | Treatment of amyloid- and epileptogenesis-associated diseases. | |
ATE412411T1 (en) | PMCOL FOR THE TREATMENT OF PROSTATE CANCER | |
ATE423780T1 (en) | MACROCYCLES FOR THE TREATMENT OF CANCER DISEASES | |
UA87292C2 (en) | Use of siramesin for treatment of malignant tumors | |
ATE454144T1 (en) | TREATMENT OF MALIGNANT NEOPLASIA | |
TW200616659A (en) | Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-included pain | |
ATE312610T1 (en) | LIPOSOMAL FORMULATIONS OF PHENYLALANINE DERIVATIVES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY RU |